Vertex Pharmaceuticals Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals

Vertex Pharmaceuticals logoVertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VRTX
  • CUSIP: 92532F10
Key Metrics:
  • Previous Close: $80.91
  • 50 Day Moving Average: $77.66
  • 200 Day Moving Average: $87.31
  • 52-Week Range: $71.46 - $103.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 80.56
  • P/E Growth: 1.46
  • Market Cap: $20.18B
  • Outstanding Shares: 248,033,000
  • Beta: 0.81
Profitability:
  • Net Margins: -13.45%
  • Return on Equity: -5.31%
  • Return on Assets: -2.40%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.98%
Additional Links:
Companies Related to Vertex Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) (?)
Ratings Breakdown: 14 Hold Ratings, 12 Buy Ratings
Consensus Rating:Hold (Score: 2.46)
Consensus Price Target: $107.80 (32.48% upside)

Analysts' Ratings History for Vertex Pharmaceuticals (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetDetails
1/20/2017Needham & Company LLCReiterated RatingHoldView Rating Details
1/17/2017Maxim GroupReiterated RatingHoldView Rating Details
1/9/2017JMP SecuritiesDowngradeMarket PerformView Rating Details
1/9/2017Robert W. BairdReiterated RatingBuy$115.00View Rating Details
1/8/2017Jefferies GroupReiterated RatingBuyView Rating Details
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
12/25/2016Piper Jaffray Cos.Set Price TargetBuy$129.00View Rating Details
12/20/2016Credit Suisse Group AGSet Price TargetBuy$100.00View Rating Details
12/15/2016Oppenheimer Holdings Inc.Initiated CoverageMarket PerformView Rating Details
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00View Rating Details
11/30/2016BMO Capital MarketsReiterated RatingMarket Perform$88.00View Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$100.00 -> $90.00View Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00View Rating Details
10/28/2016Stifel NicolausReiterated RatingBuy$109.00 -> $108.00View Rating Details
10/26/2016Leerink SwannReiterated RatingOutperform$112.00 -> $111.00View Rating Details
10/24/2016HC WainwrightDowngradeBuy -> Neutral$155.00 -> $85.00View Rating Details
10/12/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
9/13/2016Citigroup Inc.Initiated CoverageMarket PerformView Rating Details
9/13/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
7/28/2016Cowen and CompanyReiterated RatingHoldView Rating Details
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 -> $139.00View Rating Details
4/28/2016Goldman Sachs Group Inc.DowngradeBuy -> Neutral$109.00 -> $88.00View Rating Details
4/28/2016Royal Bank Of CanadaLower Price TargetOutperform$135.00 -> $115.00View Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00View Rating Details
3/15/2016Bank of America Corp.Reiterated RatingNeutral$108.00View Rating Details
2/4/2016ArgusLower Price TargetBuy$154.00 -> $140.00View Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00View Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00View Rating Details
7/7/2015BTIG ResearchLower Price TargetBuy$200.00 -> $180.00View Rating Details
6/5/2015Canaccord GenuityReiterated RatingBuy$150.00View Rating Details
(Data available from 1/21/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals (NASDAQ:VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2017        
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)
Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $1.01 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.09)($0.09)($0.09)
Q4 20163($0.07)$0.14$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vertex Pharmaceuticals (NASDAQ:VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Vertex Pharmaceuticals (NASDAQ:VRTX)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 95.28%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vertex Pharmaceuticals (NASDAQ:VRTX)
DateHeadline
bizjournals.com logoSeaport traffic gets dose of relief as Vertex joins shuttle program (NASDAQ:VRTX)
www.bizjournals.com - January 20 at 2:04 AM
nasdaq.com logoVertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat? - Nasdaq (NASDAQ:VRTX)
www.nasdaq.com - January 19 at 4:01 PM
finance.yahoo.com logoBlog Coverage Paratek Announced Enrollment Completion in Omadacycline Phase-3 Community-Acquired Bacterial Pneumonia Study (NASDAQ:VRTX)
finance.yahoo.com - January 19 at 4:00 PM
finance.yahoo.com logoVertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat? (NASDAQ:VRTX)
finance.yahoo.com - January 19 at 4:00 PM
finance.yahoo.com logoBaird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential (NASDAQ:VRTX)
finance.yahoo.com - January 19 at 4:00 PM
News IconWorld Asset Management Inc Acquires 467 Shares of Vertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX)
myhealthbowl.com - January 18 at 8:49 PM
News IconBiotechnology: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position of the day (NASDAQ:VRTX)
twincountynews.com - January 18 at 8:49 PM
News IconShould one be buying Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? (NASDAQ:VRTX)
thecelebritytruth.com - January 18 at 8:49 PM
News IconLook out for Recommendations and Insider Activity: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX)
vouxmagazine.com - January 18 at 3:46 PM
News IconJohnson Investment Counsel Inc. Decreases Position in Vertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX)
vgtoday.net - January 18 at 3:46 PM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Analyst Recommendation (NASDAQ:VRTX)
lasignare.com - January 18 at 3:46 PM
finance.yahoo.com logoWhy Vertex Pharmaceuticals (VRTX) Could Be Positioned for a Surge (NASDAQ:VRTX)
finance.yahoo.com - January 18 at 3:45 PM
finance.yahoo.com logoConcert Offers Update on Cystic Fibrosis Drug, Stock Down (NASDAQ:VRTX)
finance.yahoo.com - January 18 at 3:45 PM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bearish Target At $139 - Stock Observer (NASDAQ:VRTX)
www.thestockobserver.com - January 18 at 1:51 AM
News IconLook out for Recommendations and Insider Activity: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Post Registrar (NASDAQ:VRTX)
postregistrar.com - January 17 at 3:49 PM
News IconWall Street and Armchair Analysts Weigh in on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Heading Into ... - Wall Street Beacon (NASDAQ:VRTX)
wsbeacon.com - January 17 at 9:49 AM
fool.com logoWhy Vertex Pharmaceuticals Stock Sank 42% in 2016 (NASDAQ:VRTX)
www.fool.com - January 17 at 9:49 AM
News IconPT Review for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Aiken Advocate (NASDAQ:VRTX)
aikenadvocate.com - January 16 at 12:21 PM
News IconWill The Needle Move For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VRTX)
wsbeacon.com - January 13 at 5:44 AM
News IconRobert W. Baird Reiterates Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX)
rawgistafrica.com - January 12 at 1:33 AM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX)
ristorifrancesco.com - January 12 at 1:33 AM
uk.finance.yahoo.com logoMerck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex (NASDAQ:VRTX)
us.rd.yahoo.com - January 12 at 1:33 AM
us.rd.yahoo.com logo9:01 am Vertex Pharma licenses 4 oncology research/development programs to Merck KGaA (MKGAY (NASDAQ:VRTX)
us.rd.yahoo.com - January 12 at 1:33 AM
marketexclusive.com logoVERTEX PHARMACEUTICALS INCORPORATED (NASDAQ:VRTX) Files An 8-K Entry into a Material Definitive ... - Market Exclusive (NASDAQ:VRTX)
marketexclusive.com - January 11 at 8:32 PM
streetinsider.com logoVertex Pharma (VRTX) Announces Merck KGaA Licenses Four Oncology Research and Development Programs - StreetInsider.com (NASDAQ:VRTX)
www.streetinsider.com - January 11 at 3:31 PM
biz.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:VRTX)
biz.yahoo.com - January 11 at 3:31 PM
bizjournals.com logoVertex deals cancer drug programs to Merck KGaA for $230M (NASDAQ:VRTX)
www.bizjournals.com - January 11 at 3:31 PM
capitalcube.com logoVertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : January 11, 2017 (NASDAQ:VRTX)
www.capitalcube.com - January 11 at 3:31 PM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives An Update From Brokers (NASDAQ:VRTX)
itapunta.com - January 10 at 9:04 PM
News IconWhat directions Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) insiders are heading (NASDAQ:VRTX)
baddgoddess.com - January 10 at 9:04 PM
News IconNext Weeks Broker Price Targets For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX)
lasignare.com - January 10 at 4:03 PM
News IconSession Recap on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX)
larampadinapoli.com - January 10 at 4:03 PM
News IconAnalysts Issue Forecasts for Vertex Pharmaceuticals Incorporated's FY2016 Earnings (VRTX) (NASDAQ:VRTX)
xboxonezone.com - January 10 at 4:03 PM
seekingalpha.com logoVertex Pharmaceuticals (VRTX) presents at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:VRTX)
seekingalpha.com - January 10 at 4:03 PM
capitalcube.com logoVertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : January 10, 2017 (NASDAQ:VRTX)
us.rd.yahoo.com - January 10 at 4:03 PM
streetinsider.com logoVertex Pharma (VRTX) Provides Update Ahead of JPMorgan Conference - StreetInsider.com (NASDAQ:VRTX)
www.streetinsider.com - January 9 at 8:55 PM
forbes.com logoMonday Sector Leaders: Healthcare, Technology & Communications (NASDAQ:VRTX)
www.forbes.com - January 9 at 3:53 PM
marketexclusive.com logoInsider Trading Activity Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Director Sold 6,500 shares of Stock (NASDAQ:VRTX)
marketexclusive.com - January 9 at 3:53 PM
News IconVertex Pharmaceuticals Incorporated (VRTX) Receives Buy Rating from Jefferies Group (NASDAQ:VRTX)
larampadinapoli.com - January 9 at 3:53 PM
finance.yahoo.com logo3:59 am Vertex Pharma provides business update; sees Q4 revs above consensus (NASDAQ:VRTX)
finance.yahoo.com - January 9 at 3:53 PM
biz.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen (NASDAQ:VRTX)
biz.yahoo.com - January 9 at 3:53 PM
finance.yahoo.com logoVertex Pharma Issues Disappointing 2017 Orkambi Outlook (NASDAQ:VRTX)
finance.yahoo.com - January 9 at 3:53 PM
biz.yahoo.com logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statem (NASDAQ:VRTX)
biz.yahoo.com - January 9 at 3:53 PM
investors.com logoVertex Sales Guidance For Cystic Fibrosis Drug Orkambi Misses (NASDAQ:VRTX)
www.investors.com - January 9 at 3:53 PM
thestreet.com logoVertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected (NASDAQ:VRTX)
www.thestreet.com - January 9 at 3:53 PM
thestreet.com logoVertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis (NASDAQ:VRTX)
www.thestreet.com - January 9 at 3:53 PM
thestreet.com logoVertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business (NASDAQ:VRTX)
www.thestreet.com - January 9 at 3:53 PM
nasdaq.com logoVertex Pharma Provides Update On Business And Financial Performance (NASDAQ:VRTX)
www.nasdaq.com - January 9 at 4:01 AM
finance.yahoo.com logoVertex Provides Update on Business and Financial Performance and Research and Development Programs (NASDAQ:VRTX)
finance.yahoo.com - January 9 at 4:01 AM
thestreet.com logoVertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement (NASDAQ:VRTX)
www.thestreet.com - January 9 at 4:01 AM

Social

Vertex Pharmaceuticals (NASDAQ:VRTX) Chart for Saturday, January, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Earnings History Chart

Earnings by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Dividend History Chart

Dividend Payments by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Last Updated on 1/21/2017 by MarketBeat.com Staff